Trial document



drksid header

  DRKS00015460

Trial Description

start of 1:1-Block title

Title

Selective depletion of C-reactive protein by therapeutic apheresis (CRP apheresis) in Crohn's disease

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CAMCRO1

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

CAMCRO1 is a clinical trial to evaluate the safety and efficacy of C-reactive protein (CRP) reduction by therapeutic apheresis (CRP apheresis) in patients with Crohn's disease.
The term therapeutic apheresis generally refers to medical procedures whose therapeutic effect is based on the elimination of components of the blood to which a pathogenic function is attributed in the context of disease processes.
Elimination takes place in adsorbers outside the body in an extracorporeal circuit. To remove the pathogenic substances, blood plasma is separated from the circulation and passed through an adsorber. The purified blood plasma is then rejoined with the solid blood components and returned to the patient.
The PentraSorb® CRP adsorber used for CRP apheresis is CE certified. It is used for the selective depletion of the C-reactive protein from human cells.
As a cause for the damaging effect of the C-reactive protein, it is assumed that CRP as an inflammatory mediator favours the destruction of intestinal tissue (in combination with complement) and negatively influences the regeneration of traumatised tissue.
The CAMCRO1 study will investigate to what extent the tissue damage of the intestine can be reduced by depletion of the C-reactive protein in a relapse in Crohn's disease.
A possible protective effect of CRP apheresis with regard to damage to intestinal tissue is to be determined from the course of the disease (Crohn's disease activity index (CDAI) and Limberg score) and by determining the calprotection concentration in stool.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The CAMCRO1 study is investigating the efficacy and tolerability of C-reactive protein depletion by CRP apheresis in patients with Crohn's disease.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00015460
  •   2018/08/31
  •   [---]*
  •   no
  •   Approved
  •   EA4/070/18, Ethik-Kommission der Charité -Universitätsmedizin Berlin-
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1219-6714 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   K50 -  Crohn disease [regional enteritis]
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Each study participant will initially receive 6 apheresis treatments, each lasting approximately 4-6 hours over a period of 3 weeks (twice a week).
    The following week is used to determine the target parameters (CRP, calprotectin, CDAI, Limberg score).
    With unchanged increased CRP values (> 10 mg/l) 3 further treatments are carried out (once a week).
    The total duration of study participation is 12 weeks (including follow-up)
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Sustainable reduction of the CRP concentration in the blood.
The CRP plasma concentration is determined before and after each apheresis (maximum 9 treatments) plus 2 control measurements each in the 4th and, if relevant, 8th treatment week.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

Safety of CRP apheresis in the treatment of chronic inflammatory bowel disease (incidence of adverse effects of CRP apheresis), calprotectin concentration in faeces, Crohn's disease activity index (CDAI), Limberg score.
The corresponding parameters are determined before and after the start of apheresis treatments (4th and, if relevant, 8th week after the start of treatment).

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
  • Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2019/03/18
  •   20
  •   Multicenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   59   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Crohn's disease with active but stable symptoms, CDAI 200-350 (Crohn's disease activity index), Calprotectin > 300 µg/g stool, manifestation: colon or colon and ileum, L2-L3 (endoscopic evidence within 6 months before treatment), therapy with steroids + immunosuppressants (stable therapy and medication within the previous 6 weeks), CRP ≥ 10 mg/l, informed consent in writing, business ability

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

Age < 18 ≥ 60 years, Acute infectious disease (body temperature (auricular, sublingual) > 38.0 °C), abscesses, blind fistulas, Known hypersensitivity to therapeutic apheresis, pregnancy or lactation, Participation in other interventional tests, Dialysis-liable renal failure

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Pentracor GmbH
    • Neuendorfstr. 23 b/d
    • 16761  Hennigsdorf
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Pentracor GmbH
    • Mr.  Dr.  Burghard  Thiesen 
    • Neuendorfstr. 23 b/d
    • 16761  Hennigsdorf
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Pentracor GmbH
    • Mr.  Dr.  Burghard  Thiesen 
    • Neuendorfstr. 23 b/d
    • 16761  Hennigsdorf
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Pentracor GmbH
    • Neuendorfstr. 23 b/d
    • 16761  Hennigsdorf
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.